UPDATE : Monday, September 7, 2020
상단여백
‘Korea should lead precision medicine -- now’ by Nam Doo-hyun 2017-11-06 06:00
Celltrion’s US sales of Remsima up 48% in Q3 by Nam Doo-hyun 2017-11-01 15:51
‘Government’s undue intervention hinders growth of CROs’ by Nam Doo-hyun 2017-10-27 17:35
‘Early diagnosis more important than immunotherapy to cure lung cancer’ by Nam Doo-hyun 2017-10-25 15:22
Will induced pluripotent stem cells avoid ethical issues? by Nam Doo-hyun 2017-10-17 15:25
라인
Stem cell treatment for diabetes nears by Nam Doo-hyun 2017-10-13 15:47
Celltrion rises high in Korean stock market by Nam Doo-hyun 2017-10-11 16:11
KDA unveils new guidelines on antidiabetic therapy by Nam Doo-hyun 2017-09-29 15:35
‘Short disposable syringe increases insulin treatment effect’ by Nam Doo-hyun 2017-09-29 10:30
Korean drugmakers’ smart factories at ‘base level’ by Nam Doo-hyun 2017-09-28 16:00
라인
Drugmakers need to differentiate big data from ‘large data’ by Nam Doo-hyun 2017-09-27 17:44
Can Celltrion, Samsung make stable earnings with biosimilar? by Nam Doo-hyun 2017-09-26 17:31
‘Keytruda will beat Opdivo in US because of biomarker’ by Nam Doo-hyun 2017-09-26 15:57
With rival out, expectations growing on Genexine by Nam Doo-hyun 2017-09-25 13:52
State agency points to gender gap in medical research by Nam Doo-hyun 2017-09-21 17:13
라인
Korea lags far behind in biomedical R&D: report by Nam Doo-hyun 2017-09-21 16:14
Combination vaccines expand range of prevention by Nam Doo-hyun 2017-09-21 15:23
Sillajen emerges as biggest beneficiary of preferential listing by Nam Doo-hyun 2017-09-20 17:22
Technology transfer to Genexine imminent by Nam Doo-hyun 2017-09-19 18:02
Pharmaceutical industry leading new growth in Korea: report by Nam Doo-hyun 2017-09-18 14:50
여백
여백
여백
Back to Top